Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of “Hold” from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given an average recommendation of “Hold” by the nine research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.29.

Several analysts have recently weighed in on the company. Stifel Nicolaus lowered Neumora Therapeutics from a “buy” rating to a “hold” rating and cut their price objective for the company from $6.00 to $2.00 in a report on Friday, March 7th. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. Bank of America reaffirmed an “underperform” rating and issued a $1.00 price objective (down previously from $7.00) on shares of Neumora Therapeutics in a research note on Wednesday, April 2nd. William Blair lowered Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, March 10th. Finally, HC Wainwright cut their target price on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th.

Neumora Therapeutics Trading Down 1.9%

Neumora Therapeutics stock opened at $0.68 on Wednesday. Neumora Therapeutics has a 52 week low of $0.62 and a 52 week high of $17.19. The stock has a market cap of $109.89 million, a price-to-earnings ratio of -0.36 and a beta of 2.96. The company’s 50-day moving average price is $0.89 and its two-hundred day moving average price is $4.53.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.02). Research analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in Neumora Therapeutics in the 4th quarter worth about $61,000. PNC Financial Services Group Inc. bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at approximately $64,000. Quantbot Technologies LP acquired a new position in Neumora Therapeutics in the fourth quarter worth approximately $92,000. PEAK6 LLC acquired a new position in Neumora Therapeutics in the fourth quarter worth approximately $117,000. Finally, EntryPoint Capital LLC bought a new position in Neumora Therapeutics during the fourth quarter valued at approximately $135,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.